﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Nickan Research Institute</PublisherName>
      <JournalTitle>Journal of Renal Injury Prevention</JournalTitle>
      <Issn>2345-2781</Issn>
      <Volume>8</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2019</Year>
        <Month>06</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Hypertension in adult polycystic kidney disease: a narrative review</ArticleTitle>
    <FirstPage>122</FirstPage>
    <LastPage>126</LastPage>
    <ELocationID EIdType="doi">10.15171/jrip.2019.23</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Sarah</FirstName>
        <LastName>Mian</LastName>
      </Author>
      <Author>
        <FirstName>Yogesh</FirstName>
        <LastName>Acharya</LastName>
      </Author>
      <Author>
        <FirstName>Ranjan</FirstName>
        <LastName>Dahal</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jrip.2019.23</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>10</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>01</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <Abstract>Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disorder that impacts approximately 12 million worldwide. It is characterized by bilateral kidney enlargement and cystic growth. Hypertension (HTN) is a focal point in the management of ADPKD and is linked to a faster progression to end stage renal disease. Current novel therapies have proven to reduce the progression of renal damage. The ideal goal is to minimize risk through preventative studies and pharmacology to further increase life expectancy and quality. The purpose of this article is to highlight the importance of blood pressure management in ADPKD and review current literature to determine the most effective preventative pharmacotherapy.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Adult polycystic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antihypertensive agents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prevention and control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Renin– angiotensin–aldosterone system</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">End stage renal disease</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>